TGF-β-induced NKILA inhibits ESCC cell migration and invasion through NF-κB/MMP14 signaling

Zhiliang Lu 1 · Zhaoli Chen 1 · Yuan Li 1 · Jingnan Wang 1 · Zhirong Zhang 2 · Yun Che 1 · Jianbing Huang 1 · Shouguo Sun 1 · Shuangshuang Mao 1 · Yuanyuan Lei 1 · Yibao Gao 1 · Jie He 1 · Shuangshuang Mao 1 · Yuanyuan Lei 1 · Yibao Gao 1 · Jie He 1

Received: 3 September 2017 / Revised: 27 November 2017 / Accepted: 15 January 2018 / Published online: 29 January 2018
© The Author(s) 2018. This article is an open access publication

Abstract
The transforming growth factor β (TGF-β) signaling pathway plays anti- and pro-tumoral roles in the vast majority of cancers, and long noncoding RNAs have been reported to play key roles in the highly contextual response process. However, the roles of long noncoding RNAs (lncRNAs) in TGF-β signaling in esophageal squamous cell carcinoma (ESCC) remain unknown. In this study, we performed RNA-seq to compare lncRNAs expression levels between TGF-β1-treated and untreated ESCC cells and observed that NF-kappaB-interacting lncRNA (NKILA) was remarkably upregulated by the classical TGF-β signaling pathway. RNA profiling of 39 pairs ESCC tumor and adjacent nontumor samples using RT-qPCR demonstrated that NKILA is significantly downregulated in ESCC tumor tissues, and NKILA expression levels were significantly decreased in advanced tumor tissues (III and IV) compared to early stages (I and II) (p < 0.01). Gain- and loss-of-function assays showed that NKILA inhibited ESCC cell metastasis in vitro and in vivo, and mechanism studies showed that NKILA repressed MMP14 expression by inhibiting IκBα phosphorylation and NF-κB activation. Collectively, these findings suggest that the TGF-β-induced lncRNA NKILA has potential as an antimetastasis therapy.

Key messages
• Long noncoding RNA NKILA could be remarkably upregulated by classical TGF-β signal pathway in ESCC.
• NKILA was significantly downregulated in esophageal squamous cell carcinoma and negatively correlated with TNM stage.
• NKILA inhibits ESCC cell metastasis via repressing MMP14 expression by suppressing the phosphorylation of IκBα and NF-κB activation.

Keywords NF-kappaB-interacting lncRNA · Transforming growth factor β · Long noncoding RNA · Tumor metastasis · ESCC

Introduction
Esophageal cancer is one of the leading causes of cancer-related death worldwide, and half of the cases of the disease occur in China [1]. Approximately 90% of the cases of esophageal cancer occurring in China and worldwide are squamous cell carcinomas [2–4]. The overall 5-year survival rate of the disease ranges from only 15 to 25%, and the poor outcomes of esophageal cancer are related to its diagnosis at metastatic stages in affected patients, even in cases in which the tumors are superficial [5]. The molecular mechanisms that mediate the metastatic cascade remain largely unknown. Improving the understanding of the molecular mechanisms underlying cancer progression and metastasis may accelerate the
development of effective metastasis-targeting therapies for patients with esophageal squamous cell carcinoma (ESCC).

The multifunctional cytokine TGF-β orchestrates an intricate and context-dependent signaling network to modulate tumorigenesis and disease progression. The TGF-β pathway promotes cell cycle arrest and apoptosis in early stage tumors but promotes tumor progression and metastasis in advanced disease, either by inactivating core components of the pathway, such as TGF-β receptors, or by inducing downstream alterations that disable only the tumor-suppressive arm of the pathway [6–8]. The role of TGF-β-induced epithelial-mesenchymal transition (EMT) in cancer cell metastasis has been well-established; however, the necessity of EMT and its opposing process, mesenchymal-epithelial transition (MET), in tumor cell metastasis is still hotly debated [9–11]. A better understanding of the specific and time-dependent downstream effectors of TGF-β signaling is urgently needed to accelerate the development of targeted TGF-β signaling pathway therapies.

Long noncoding RNAs (lncRNAs) are a class of transcripts longer than 200 nucleotides that do not appear to have coding potential [12, 13]. Many studies recently showed that lncRNAs are frequently deregulated in a range of cancers and participate in several biological processes, such as cell cycle progression, cell apoptosis, and cell metastasis [14, 15]. Thus far, the exact mechanisms through which lncRNAs perform their functions remain unknown; however, most lncRNAs appear to perform their bio-functions by regulating vital signaling pathways in cancer, such as the TGF-β signaling pathway, one of the most important cancer cell signaling pathways [15]. For example, the lncRNA-ATB (a lncRNA activated by the TGF-β pathway) promoted invasion–metastasis cascade activity and organ colonization by competitively binding with miR-200 and stabilizing IL-11 mRNA [16]. In this study, we found that NF-kappaB-interacting lncRNA (NKILA) was remarkably upregulated by TGF-β1 and focused on the role of NKILA in TGF-β signaling and the invasion–metastasis cascade.

Materials and methods

Tissue samples and clinical data collection

A cohort of 39 ESCC tissues and pair-matched adjacent normal esophageal tissues (collected postoperatively from April 2008 to June 2009) were obtained from the Department of Thoracic Surgery of the Cancer Hospital of the Chinese Academy of Medical Sciences. The pathological diagnoses for these 39 patients were obtained. None of patients received radiotherapy or chemotherapy before surgery, nor were any of them diagnosed with any other cancers within 3 years before surgery. The patients with ESCC were staged according to the TNM staging system (the 7th edition) of the American Joint Committee on Cancer, and data pertaining to the clinicopathological characteristics of these patients were collected. The tumor tissues and adjacent normal tissues from these 39 patients were snap-frozen in liquid nitrogen immediately after resection and were stored at −80 °C until used in this study.

Cell culture and stable cell line construction

A total of seven cell lines, including six ESCC cell lines (KYSE30, KYSE70, KYSE150, KYSE180, KYSE450, and KYSE510) and the immortalized normal human esophageal epithelial cell line Het-1a, were used in this study. The cell lines were cultured as described previously [17]. We confirmed cell line identities by matching the short-tandem repeat (STR) profile of each line to the registered information in the DSMZ online STR database. TNF-α and IL-1β were purchased from Peprotech (USA) and used at a concentration of 10 ng/ml, and TGF-β1 was purchased from R&D (USA) and used at a concentration of 5 ng/ml. The treatment time was 24 h unless otherwise specified. To inhibit TGF-β and NF-κB signaling, we added 10 μM JSH-23 (Selleck, USA) or 5 μM SB505124 (Selleck, USA) to the cell culture media 30 min prior to the specified treatments.

Full-length NKILA cDNA was compounded by Generay (Shanghai, China) and ligated into a pCDH-CMV-MCS-EF1-GFP + Puro (CD513B-1) vector. Non-targeting control shRNA and two shRNAs against NKILA (sh1 and sh2, respectively) were obtained from OBiO (Shanghai, China). The transfection and lentivirus packaging were performed as described previously [17].

Next-generation sequencing of the transcriptome

KYSE30 and KYSE180 cells were treated with or without 5 ng/ml recombinant TGF-β1 for 72 h. Total RNA was then extracted from the treated and untreated KYSE30 and KYSE180 cells. For the details of sample preparation, library preparation, and sequencing, see the supplementary material. Gene expression levels were determined based on FPKM (fragments per kilobase per million reads) values. We used a fold change ≥2.0 as our threshold for screening upregulated and downregulated lncRNAs or mRNAs.

RNA extraction, RT-qPCR, western blotting, and transwell assay

RNA extraction, RT-qPCR, western blotting, and transwell assay were performed as described previously [18]. The
Fig. 1 TGF-β-induced EMT markers in KYSE30 and KYSE180 cells. 

a Venn diagram of the mRNAs that are differentially expressed between KYSE30 and KYSE180 cells treated with or without TGF-β, as demonstrated by RNA-seq. 

b Heat map representation of RNA-seq data pertaining to the expression levels of EMT-related genes in KYSE30 and KYSE180 cells treated with TGF-β1 for 72 h and control cells. 

c Heat map of the expression of EMT-related genes in KYSE30 and KYSE180 cells treated with TGF-β1 for 72 h and control cells, as demonstrated by RT-qPCR. 

d Functionally grouped network in which enriched KEGG pathways and GO biological function terms served as nodes linked based on the kappa score levels (≥ 0.55). Only the label of the most significant term in each group is shown. The KEGG pathway and GO biological functional terms were enriched by the Cytoscape Cluego plugin. Octagon represents the KEGG pathway. Ellipse represents the GO terms. The node size represents the significance of the term enrichment; thus, the larger the node size, the smaller the corrected p value. Different colors represent different functional groups.
The following antibodies were used for western blot analysis: GAPDH (CST), p65 (CST), p-p65 (CST), IκBα (CST), p-IκBα (CST), MMP14 (CST), histone 3 (Abcam), and tubulin (Abcam). The primers used for PCR and the sequences of the shRNAs used in the study are shown in Table S1.

Chromatin immunoprecipitation (ChIP) assay

KYSE30 cells treated with PBS or recombinant TGF-β1 for 30 min were used to perform ChIP assay using an anti-Smad2/3 antibody (CST) and an EZ-Magna ChIP Chromatin Immunoprecipitation Kit (Millipore), according to the
LncRNA NKILA is upregulated by TGF-β

To identify the lncRNAs that are regulated by TGF-β and mediate the regulatory effects of TGF-β on cell metastasis, we treated KYSE30 and KYSE180 ESCC cells with TGF-β1 continuously for 72 h. The treatment caused the cells to undergo EMT, based on our subsequent observation that the cells had a spindle-shaped appearance (Fig. S1A), and promoted cell migration and invasion, as demonstrated by the wound-heeling (Fig. S1B) and transwell (Fig. S1C and D) assays, respectively. We then used whole-transcriptome RNA-seq to compare mRNA and lncRNA expression levels between the TGF-β1-treated and untreated cell lines. We found that 249 mRNAs were upregulated, and 468 mRNAs were downregulated in TGF-β1-treated KYSE30 and KYSE180 cells compared with the corresponding untreated cells (Fig. 1a). The RNA-seq results indicated that TGF-β1 treatment led to EMT gene expression signature with high expression level of mesenchymal markers and low expression level of epithelial markers (Fig. 1b). To evaluate RNA-seq accuracy, we confirmed the expression of several essential EMT markers, including CDH2, VIM, ZEB1, SNAI1, and CDH1, by RT-qPCR (Fig. 1c). Functionally grouped networks [19] of enriched KEGG pathways and GO biological functional terms indicated that many TGF-β-responsive signaling pathways and biological processes were significantly enriched in the TGF-β1-treated cell lines (Fig. 1d and Fig. S2), confirming that the RNA-Seq results were reliable.

We found that 167 lncRNAs were upregulated, and 290 lncRNAs were downregulated in both TGF-β1-treated cell lines compared with the corresponding untreated cell lines (Fig. 2a). We then limited our search to lncRNAs with FPKM values ≥ 1 and expression levels differing by more than ≥ 4.0-fold between treated and untreated cells. We identified seven lncRNAs whose expression was upregulated and four lncRNAs whose expression was downregulated in treated cells compared with untreated cells and verified the expression most of the lncRNAs by RT-qPCR (Fig. 2b). Of those lncRNAs, the lncRNA whose expression was most upregulated in TGF-β1-treated cells was the lncRNA NKILA (Fig. 2b), whose expression was consistently found to be upregulated by more than 10-fold in both ESCC cell lines compared with the corresponding untreated cell lines (Fig. 2c). NKILA expression peaked at 24 h after TGF-β1 treatment and remained elevated for up to 96 h after treatment in KYSE30 and KYSE180 cells (Fig. 2d). NKILA is a lncRNA encoded by a gene on chromosome 20q13 and was initially identified as an NF-κB-induced lncRNA in breast cancer [20]. To determine whether TGF-β signaling is responsible for NKILA expression, we used the TGF-β receptor inhibitor SB505124 and the NF-κB nuclear translocation inhibitor JSH-23 to...
abrogate the effects of TGF-β1 treatment on NKILA expression. The results showed that SB505124 completely inhibited TGF-β1-induced NKILA expression in KYSE30 and KYSE180 cells but not JSH-23 (Fig. 2e). To investigate whether NKILA is regulated by the classical TGF-β pathway, we performed ChIP assay using anti-Smad2/3 antibodies. We found that TGF-β1 treatment led to a significant increase of enriched NKILA promoter sequence, which implied that the Smad2/3 complex was recruited to the promoter of the NKILA gene by TGF-β1 treatment (Fig. 2f). We also observed that the Smad3 phosphorylation selective inhibitor SIS3 could restore back TGFβ1-induced NKILA expression (Fig. S3). In addition, nuclear and cytosolic fraction isolation studies and RT-qPCR showed that NKILA was expressed in the nucleus and cytoplasm simultaneously in KYSE30 and KYSE180 cells, a result that was inconsistent with those of previous reports regarding NKILA expression in breast cancer and was probably due to cell-specific differences in NKILA regulation. GAPDH and nucleic RNA NEAT1 were used as fractionation indicators (Fig. 2g). Taken together, these results suggested that NKILA was dramatically upregulated by the classical TGF-β signaling pathway in ESCC cells.

**NKILA negatively regulated tumor migration and invasion in vitro**

Given the involvement of NKILA in the TGF-β signaling, which plays a vital role in cell migration and invasion, we speculated that NKILA plays an important role in tumor metastasis. First, we generated two NKILA-knockdown plasmids (named sh1 and sh2, respectively) and assessed the efficiency with which the plasmids knocked down NKILA expression via RT-qPCR. Both knockdown cell clones displayed decreases in NKILA expression of more than 70% regardless of whether the cells were treated with TGF-β1 (Fig. 3a, b). Then, we performed transwell assay to investigate the effects of NKILA expression on the malignant behavior of ESCC cells. As shown in Fig. 3c, d, the migration and invasion abilities of KYSE30 and KYSE180 cells were significantly enhanced when NKILA expression levels were decreased. Conversely, NKILA expression was significantly increased in KYSE30 and KYSE180 cells with stable NKILA overexpression compared with cells transfected with mock-vehicle controls (Fig. 3e, f). In addition, NKILA overexpression significantly suppressed the migration and invasion ability of both ESCC cell lines (Fig. 3g, h).

**NKILA inhibited tumor metastasis in vivo**

To evaluate the effect of NKILA expression on ESCC cell metastasis in vivo further, we performed lung colonization assay by injecting cells directly into the tail veins of non-obese diabetic (NOD)-SCID mice. The number of metastatic nodules in the lungs was counted 7 weeks after tail vein injection. NKILA-overexpressing cells displayed decreased lung colonization rates and formed less metastatic tumors in the lung, whereas NKILA-knockdown cells displayed significantly increased metastatic nodule formation compared with mock-vehicle control-transfected cells (Fig. 4a, b). H&E-stained images of lung tissues isolated from the mice are shown in Fig. 4c. These data demonstrated that NKILA restrained tumor metastasis in vivo.

**NKILA was downregulated in the tumor tissues of patients with ESCC**

NKILA expression levels in tumor tissues and matched adjacent normal tissues from 39 patients with ESCC were measured by RT-qPCR, which showed that NKILA expression was significantly reduced in ESCC tissues compared with adjacent normal esophageal tissues (p < 0.001, Fig. 4d, e). In addition, NKILA expression levels were significantly decreased in advanced tumor tissues compared with early stage tumor tissues (p < 0.01, Fig. 4f). NKILA expression was also lower in tumor tissues with lymph node metastasis than in tumor tissues without lymph node metastasis, but the difference between the two groups was not significant (p = 0.076, Fig. S4), perhaps because the sizes of the samples were small. The 39 patients with ESCC were classified into the following two groups according to the NKILA expression level in their tumor tissues: a higher NKILA expression group (n = 19, NKILA expression level > median expression level) and a low NKILA expression group (n = 17, NKILA expression level ≤ median level). NKILA downregulation in ESCC was significantly associated with T stage (p < 0.05) and clinical stage (p < 0.05). However, there were no correlations between NKILA expression and age, gender, smoking, pathologic grade, and tumor size (p > 0.05) (Table S2). In addition, NKILA expression was significantly downregulated in the abovementioned six ESCC cell lines compared with the human esophageal epithelial cell line Het-1a (Fig. 4g). All these data suggested that NKILA expression was significantly downregulated in ESCC tumor tissues and implicated NKILA in ESCC tumorigenesis and progression.
NKILA inhibited IkBα phosphorylation and NF-κB activation in ESCC cells

NKILA has been reported to interact with and influence the activation of NF-κB signaling in breast cancer [20]. We detected IkBα and p65 phosphorylation levels in NKILA-overexpressing and silenced ESCC cells and found that TNF-α-induced IkBα and p65 phosphorylation was inhibited by ectopic NKILA expression in KYSE30 and KYSE180 cells but was enhanced by NKILA silencing in both cell lines (Fig. 5a, b). Furthermore, we found that ectopic NKILA expression markedly inhibited TNF-α-induced p65 nuclear translocation in KYSE30 and KYSE180 cells compared with mock-vehicle control-transfected cells, while NKILA silencing significantly prolonged p65 translocation (to 24 h) in KYSE30 and KYSE180 cells compared with mock-vehicle control-transfected cells, results consistent with those mentioned above (Fig. 5c, d). These results suggested that NKILA suppressed NF-κB activation by inhibiting IKK-induced IkBα phosphorylation.

NKILA inhibited ESCC cell migration and invasion through NF-κB/MMP14 signaling

Matrix metalloproteinases (MMPs), which play a central role in extracellular matrix turnover and cancer cell migration and invasion [21], are one of the most important downstream regulators of NF-κB-induced cell metastasis. To determine how NKILA regulates cell migration and invasion, we detected MMP2, MMP9, and MMP14 protein expression levels in NKILA-overexpressing or silenced ESCC cells. We found that MMP14 expression levels were remarkably attenuated by ectopic NKILA expression. In contrast, silencing NKILA elevated MMP14 expression levels in KYSE30 and KYSE180 cells (Fig. 5a, b). Furthermore, NKILA-induced changes in MMP14 expression levels were completely...
abrogated by the NF-κB translocation inhibitor JSH-23 (Fig. S5). Coincidentally, our mRNA microarray data [22] pertaining to 119 pared tissues from patients with ESCC (Fig. 5e), microarray data collected by Hua Su [23] (Fig. 5f), and ESCC RNA-seq data from TCGA (Fig. 5g) showed that MMP14 expression was significantly upregulated in ESCC tissues compared with paired normal tissues. To determine whether NF-κB/MMP14 signaling is responsible for NKILA-regulated cell migration and invasion, we used TNF-α to induce NF-κB pathway activation and consequently promote KYSE30 and KYSE180 cell migration and invasion. The results showed that the decreases in migration and invasion ability caused by NKILA overexpression were reversed by TNF-α stimulation (Fig. 6a, b). Conversely, the NF-κB translocation inhibitor JSH-23 abrogated the enhancements of cell migration and invasion ability induced by NKILA silencing (Fig. 6c, d). Collectively, all these results suggested that NKILA regulated ESCC cell migration and invasion through NF-κB/MMP14 signaling.

**Discussion**

Numerous studies have found that the TGF-β signaling pathway plays vital roles in regulating extracellular matrix (ECM) production and tumor metastasis; however, the mechanisms underlying its effects remain unclear. In recent years, an increasing number of lncRNAs have been found to be involved in the TGF-β signaling pathway in various cancers [24] and to complement the complicated biological mechanisms through which TGF-β signaling regulates cancer development and progression. TGF-β signaling is a key player in the genesis and development of ESCC, and the output of the TGF-β response is highly contextual. Given the growing number of lncRNAs reported to be involved in ESCC [25–29], we speculated that lncRNA may also be involved in the TGF-β signaling pathway. In our study, we found that the lncRNA NKILA was dramatically induced by TGF-β1 in KYSE30 and KYSE180 ESCC cells via RNA-seq, findings that were validated by RT-qPCR. NKILA was reported to be upregulated by more than 12-fold by TNF-α- and IL-1β-induced NF-κB activation in breast cancer [20]. However, in this study, NKILA expression levels only doubled in ESCC cells treated with TNF-α or IL-1β. More importantly, TGF-β1-induced NKILA expression could not be reversed by the NF-κB nuclear translocation inhibitor JSH-23, while TNF-α- or IL1β-induced NKILA upregulation was completely inhibited by the TGF-β receptor inhibitor SB505124 (Fig. S6). Based on these results, as well as the ChIP assay results, which are shown in Fig. 2f, we concluded that NKILA is directly upregulated by the TGF-β classical signaling pathway, which suggested that NKILA may be involved in TGF-β signaling in ESCC cells. We performed loss- and gain-of-function assays to investigate the role of NKILA in tumor cell malignant behavior. The results showed that NKILA attenuated ESCC cell migration and invasion in vitro and lung colonization in vivo. Moreover, NKILA expression levels, which were remarkably reduced in ESCC tumor tissues compared with adjacent noncancerous tissues, were negatively correlated with TNM stages and lymph node metastasis (no statistical significance). These findings suggested that NKILA was involved in TGF-β signaling and acts as a tumor suppressor in ESCC.

Metastasis is the leading cause of death in patients with cancer. Invasive cell migration through tissue barriers requires pericellular remodeling of the ECM, a process executed by cell-surface proteases, particularly MMPs. Several ECM-degrading proteolytic enzymes, such as MMP-1, 2, 13, and 14 and cathepsins B, K, and L, have been implicated in this process; however, MMP-14 may be the critical and rate-limiting enzyme in collagen turnover [21, 30, 31]. Previous studies and our microarray data showed that MMP14 expression is upregulated in ESCC tumor tissues and is associated with a poor prognosis [32–36], findings that are attributable at least in part to the metastasis-promotion function of MMP14 in ESCC cells. In the present study, we found that NKILA decreased MMP14 expression levels by mediating 1kBα phosphorylation and NF-κB translocation to the nucleus and consequently weakened ESCC cell migration and invasion ability. In addition, the effects of NKILA on MMP14 expression and ESCC cell metastatic potential were abrogated by the NF-κB translocation inhibitor JSH-23 in KYSE30 and KYSE180 cells. Collectively, these findings indicate that NKILA-regulated migration and invasion is mediated by the NF-κB/MMP14 signaling pathway in ESCC cells.

TGF-β can be secreted by tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFS), as well as cancer cells, and is constitutively active in many tumors [37]. Mounting numbers of studies have established that the TGF-β pathway is an essential factor in cancer development and plays either a tumor-suppressing or a tumor-promoting role depending on the concentrations of different ligands. TGF-β signaling pathway activity duration and intensity are critical determinants of the biological responses of TGF-β family members [38, 39]. Several negative regulators of the TGF-β pathway, for example, prostate transmembrane protein androgen-induced 1 (PMEPA1) [40] and thrombospondin-1 (THBS1) [41, 42], certain I-Smads (i.e., Smad6 and Smad7), Smad ubiquitination regulatory factors (Smurfs) [43], and TG-interacting factor (TGIF) [44], have been shown to be tumor suppressors. Many of these regulators are transcribed by TGF-β but participate in negative feedback loops to prevent sustained or excessive TGF-β pathway activation. We found that NKILA, a TGF-β-induced lncRNA, is also involved in these negative-feedback networks and serves as tumor suppressor by inhibiting ESCC progression and metastasis. In
In the present study, we found that NKILA expression was decreased in advanced ESCC tumor tissues and that NKILA inhibited ESCC cell metastasis in vitro and in vivo and thus compliments the complicated networks through which TGF-β signaling regulates cancer progression and metastasis.

In summary, our research demonstrated that NKILA acts downstream of the TGF-β signaling pathway and inhibits cell invasion and metastasis by inhibiting IκBα phosphorylation and NF-κB activation and, consequently, suppressing MMP14 expression. Moreover, NKILA expression levels are decreased in the advanced tumor tissues of patients with ESCC. More samples are needed to evaluate the role of NKILA in ESCC to determine its clinical value. The observations discussed herein indicate that NKILA has potential as a target in the treatment of ESCC.

**Fig. 5** NKILA suppressed NF-κB signaling activation and MMP14 expression. **a, b** Western blotting showing the expression of crucial components (IκB, p-IκB, p65, p-p65) of the NF-κB signaling pathway and MMP14 in stable KYSE30 (a) or KYSE180 (b) cell clones treated with or without TNF-α for the indicated time. The left panel features representative images, and the right panel features a statistical diagram. GAPDH was the loading control. **c, d** Western blotting for nuclear and cytoplasmic p65 in stable KYSE30 (c) and KYSE180 (d) cell clones treated with or without TNF-α. GAPDH and histone 3 (H3) were the loading controls for the cytoplasm and nucleus, respectively. The left panel features representative images, and the right panel features a statistical diagram. Data are shown as the mean ± SD, n = 3. **e-g** MMP14 mRNA expression levels were calculated from three data sets, GSE53625, GSE23400, and TCGA ESCC RNA-seq data (http://xena.ucsc.edu/). The former two data sets included cDNA microarray data for matched normal and ESCC tissues. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test)

**Fig. 6** NKILA regulates ESCC cell migration and invasion via the NF-κB/MMP14 pathway. **a, b** Migration and invasion of KYSE30 and KYSE180 cells stably expressing NKILA or mock-vehicle controls after treatment with or without TNF-α, as measured by Chamber assay. **c, d** Migration and invasion of stable KYSE30 and KYSE180 NKILA-knockdown or mock-vehicle control cell clones exposed to TNF-α and treated with or without JSH-23 (JSH), as measured by Chamber assay. The left panel features representative images, and the right panel features a statistical diagram. Data are shown as the mean ± SD, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test)
Acknowledgements This work was supported by the National Natural Science Foundation of China [grant number 81502060], the National Key Research and Development Program of China [grant numbers 2016YFC1030201, 2016YFC0901401], the Institutional Fundamental Research Funds (grant numbers JK2014B14, 2017PT32001), and the CAMS Initiative for Innovative Medicine (CIFMS) (grant number 2017-2M-I-1005). We thank Dr. Sun Nan, Ms. Zhou Fang and Ms. Xiong Meihua for their administrative help. We thank the American Journal Experts for editorial assistance.

Compliance with ethical standards

The authors declare that they have no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Conflict of interest The authors declare that they have no conflicts of interest.

References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108
2. Rustgi AK, El-Serag HB (2014) Esophageal Carcinoma. New Engl J Med 371(26):2499–2509
3. He YT, Li DJ, Liang D, Jin J, Wen DG, Chen WQ, He J (2017) Estimated of esophageal cancer incidence and mortality in China, 2013. Zhonghua zhong liu za zhi [Chinese J Oncology] 39(4):315–320
4. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132
5. Pennathur A, Gibson MK, Jobe BA, Luketich JD (2013) Oesophageal carcinoma. Lancet 381(9864):400–412. https://doi.org/10.1016/S0140-6736(12)60643-6
6. Padua D, Massague J (2009) Roles of TGFbeta in metastasis. Cell Res 19(1):89–102
7. Massague J (2008) TGFbeta in cancer. Cell 134(2):215–230
8. Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, de Gramont A (2015) Targeting the TGFbeta pathway for cancer therapy. Pharmacol Ther 147:22–31
9. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J et al (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527(7579):472–476
10. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H, Wu CC, LeBleu VS, Kalluri R (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527(7579):525–530
11. Maheswaran S, Haber DA (2015) Cell fate: transition loses its invasive edge. Nature 527(7579):452–453
12. Rinn JL, Chang HY (2012) Genome regulation by long noncoding RNAs. Annu Rev Biochem 81(1):145–166
13. Quinn JJ, Chang HY (2016) Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet 17(1):47–62
14. Huarte M (2015) The emerging role of lncRNAs in cancer. Nat Med 21(11):1253–1261
15. Schmitt AM, Chang HY (2016) Long noncoding RNAs in cancer pathways. Cancer Cell 29(4):452–463
16. Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, Liu F, Pan W, Wang TT, Zhou CC et al (2014) A long noncoding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 25(5):666–681
17. Gao YB, Chen ZL, Li JG, Xu XD, Shi XJ, Sun ZM, Zhang F, Zhao ZR, Li ZT, Liu ZY, Zhao YD, Sun J, Zhou CC, Yao R, Wang SY, Wang P, Sun N, Zhang BH, Dong JS, Yu Y, Luo M, Feng XL, Shi SS, Zhou F, Tan FW, Qiu B, Li N, Shao K, Zhang LJ, Zhang LJ, Xu Q, Gao SG, He J (2014) Genetic landscape of esophageal squamous cell carcinoma. Nat Genet 46(10):1097–1102
18. Lu Z, Li Y, Wang J, Che Y, Sun S, Huang J, Chen Z, He J (2017) Long non-coding RNA NKILA inhibits migration and invasion of non-small cell lung cancer via NF-kappaB/snail pathway. J Experimental Clinical Cancer Res : CR 36(1):54
19. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pages F, Trajanoski Z, Galon J (2009) ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25(8):1091–1093
20. Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X, Lin L, Yao H, Su F, Li D, Zeng M, Song E (2015) A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis. Cancer Cell 27(3):370–381
21. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1):52–67
22. Li J, Chen Z, Tian L, Zhou C, He MY, Gao Y, Wang S, Zhou F, Shi S, Feng X, Sun N, Liu Z, Skogerboe G, Dong J, Yao R, Zhao Y, Sun J, Zhang B, Yu Y, Shi X, Luo M, Shao K, Li N, Qiu B, Tan F, Chen R, Hu Q (2014) LncRNA NKILA as a transcriptional co-repressor of lung cancer. Cancer Res 74(17):5096–5106
23. Su H, Hu N, Yang HH, Wang C, Takikita M, Wang QH, Lin JZ, Goldstein AM, Lee MP, Taylor PR (2011) Global gene expression profiling and validation in esophageal squamous cell carcinoma and its association with clinical phenotypes. Proc Natl Acad Sci U S A 108(12):4763–4768
24. Wang J, Shao N, Ding X, Tan B, Song Q, Wang N, Jia Y, Ling H, Cheng Y (2015) Crosstalk between transforming growth factor-beta signaling pathway and long non-coding RNAs in cancer. Cancer Lett 370(2):296–301
25. Wang CM, Wu QQ, Li SQ, Chen FJ, Tuo L, Xie XW, Tong YS, Ji L, Zhou GZ, Cao G, Wu M, Lv J, Shi WH, Cao XF (2014) A long noncoding RNA activated by TGFbeta-1 promotes esophageal squamous carcinoma cell proliferation and correlates with advanced clinical stage. Dig Dis Sci 59(3):597–604
26. Li W, Zheng J, Deng J, You Y, Wu H, Li N, Lu J, Zhou Y (2014) Increased levels of the long intergenic non-protein coding RNA POU5F3 promote DNA methylation in esophageal squamous cell carcinoma cells. Gastroenterology 147:1714–1726.e1715
27. Wu W, Bhagat TD, Yang X, Song JH, Cheng Y, Agarwal R, Abraham JM, Ibrahim S, Bartenstein M, Hassan Z et al (2013) Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 144:956–966.e954
28. Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, Abraham JM, Ibrahim S, Ravich W, Roland BC, Khashab M, Singh VK, Shin EJ, Yang X, Verma AK, Meltzer SJ, Mori Y (2014) Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells. Gut 63(6):881–890

29. Chen FJ, Sun M, Li SQ, Wu QQ, Ji L, Liu ZL, Zhou GZ, Cao G, Jin L, Xie HW, Wang CM, Lv J, De W, Wu M, Cao XF (2013) Upregulation of the long non-coding RNA hotair promotes esophageal squamous cell carcinoma metastasis and poor prognosis. Mol Carcinog 52(11):908–915

30. Friedl P, Wolf K (2008) Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res 68(18):7247–7249

31. Sabeh F, Ota I, Holmbeck K, Birkedal-Hansen H, Soloway P, Balbin M, Lopez-Otin C, Shapiro S, Inada M, Krane S, Allen E, Chung D, Weiss SJ (2004) Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 167(4):769–781

32. Pang L, Li Q, Li S, He J, Cao W, Lan J, Sun B, Zou H, Wang C, Liu R, Wei C, Wei Y, Qi Y, Hu J, Liang W, Zhang WJ, Wan M, Li F (2016) Membrane type 1-matrix metalloproteinase induces epithelial-to-mesenchymal transition in esophageal squamous cell carcinoma: observations from clinical and in vitro analyses. Sci Rep 6(1):22179

33. Akanuma N, Hoshino I, Akutsu Y, Murakami K, Isozaki Y, Maruyama T, Yusup G, Qin W, Toyozumi T, Takahashi M, Suito H, Hu X, Sekino N, Matsubara H (2014) MicroRNA-133a regulates the mRNAs of two invadopodia-related proteins, FSCN1 and MMP14, in esophageal cancer. Br J Cancer 110(1):189–198

34. Kwiatkowska A, Kijewska M, Lipko M, Hibner U, Kaminska B (2011) Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression. Biochim Biophys Acta 1813(5):655–667

35. Groblewska M, Siewko M, Mroczko B, Szmukowski M (2012) The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol 50(1):12–19

36. Pahwa S, Stawikowski MJ, Fields GB (2014) Monitoring and inhibiting MT1-MMP during cancer initiation and progression. Cancers 6(1):416–435

37. Pickup M, Novitskiy S, Moses HL (2013) The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer 13(11):788–799

38. Wakefield LM, Hill CS (2013) Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat Rev Cancer 13(5):328–341

39. Massague J (2012) TGFbeta signalling in context. Nat Rev Mol Cell Biol 13(10):616–630

40. Watanabe Y, Itoh S, Goto T, Ohnishi E, Inamitsu M, Itoh F, Satoh K, Wiercinska E, Yang W, Shi L, Tanaka A, Nakano N, Mommaas AM, Shibuya H, ten Dijke P, Kato M (2010) TMEPAI, a transmembrane TGF-β-inducible protein, sequesters Smad proteins from active participation in TGF-β signaling. Mol Cell 37(1):123–134. https://doi.org/10.1016/j.molcel.2009.10.028

41. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Bouck N (1998) Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93(7):1159–1170

42. Breitkopf K, Sawitzka I, Westhoff JH, Wickert L, Dooley S, Gressner AM (2005) Thrombospondin 1 acts as a strong promoter of transforming growth factor beta effects via two distinct mechanisms in hepatic stellate cells. Gut 54(5):673–681

43. Massague J, Seoane J, Wotton D (2005) Smad transcription factors. Genes Dev 19(23):2783–2810

44. Itoh S, ten Dijke P (2007) Negative regulation of TGF-beta receptor/Smad signal transduction. Curr Opin Cell Biol 19(2):176–184